05:54 PM EDT, 05/22/2025 (MT Newswires) -- Pfizer ( PFE ) and Astellas Pharma said long-term follow-up results from a phase 3 clinical trial demonstrated a 30% reduction in the risk of death for men with metastatic hormone-sensitive prostate cancer.

The study, which followed patients for five years, found that treatment with XTANDI plus androgen deprivation therapy improved survival rates compared with placebo plus ADT, the companies said Thursday in a statement.

The data will be presented at the American Society of Clinical Oncology's annual meeting in Chicago on June 3.